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Lipid peroxidation can be described generally as a process under which oxidants such as free radicals attack lipids containing
carbon-carbon double bond(s), especially polyunsaturated fatty acids (PUFAs). Over the last four decades, an extensive body of
literature regarding lipid peroxidation has shown its important role in cell biology and human health. Since the early 1970s, the total
published research articles on the topic of lipid peroxidation was 98 (1970–1974) and has been increasing at almost 135-fold, by up to
13165 in last 4 years (2010–2013). New discoveries about the involvement in cellular physiology and pathology, as well as the control
of lipid peroxidation, continue to emerge every day. Given the enormity of this field, this review focuses on biochemical concepts of
lipid peroxidation, production,metabolism, and signalingmechanisms of twomain omega-6 fatty acids lipid peroxidation products:
malondialdehyde (MDA) and, in particular, 4-hydroxy-2-nonenal (4-HNE), summarizing not only its physiological and protective
function as signaling molecule stimulating gene expression and cell survival, but also its cytotoxic role inhibiting gene expression
and promoting cell death. Finally, overviews of in vivomammalian model systems used to study the lipid peroxidation process, and
common pathological processes linked to MDA and 4-HNE are shown.
This review paper is dedicated to
Dr. Alberto Machado
1. Lipids Overview of Biological Functions
Lipids Are Classically Divided into Two Groups: Apolar and
Polar. Triglycerides (apolar), stored in various cells, but
especially in adipose (fat) tissue, are usually the main form of
energy storage in mammals [1, 2]. Polar lipids are structural
components of cell membranes, where they participate in the
formation of the permeability barrier of cells and subcellular
organelles in the form of a lipid bilayer. The major lipid type
defining this bilayer in almost all membranes is glycerol-
based phospholipid [3]. The importance of the membrane
lipid physical (phase) state is evidenced by the fact that lipids
may control the physiological state of a membrane organelle
by modifying its biophysical aspects, such as the polarity
and permeability. Lipids also have a key role in biology as
signaling molecules.
Lipids as SignalingMolecules.Themain enzymes that generate
lipid signaling mediators are lipoxygenase, which medi-
ate hydroperoxyeicosatetraenoic acids (HPETEs), lipoxins,
leukotrienes, or hepoxilins biosynthesis after oxidation of
arachidonic acid (AA) [4, 5], cyclooxygenase that produces
prostaglandins [4], and cytochrome P-450 (CYP) which
generates epoxyeicosatrienoic acids, leukotoxins, thrombox-
ane, or prostacyclin [4]. Lipid signaling may occur via
activation of a variety of receptors, including G protein-
coupled and nuclear receptors. Members of several different
lipid categories have been identified as potent intracellular
signal transduction molecules. Examples of signaling lipids
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include (i) two derived from the phosphatidylinositol phos-
phates, diacylglycerol (DAG) and inositol phosphates (IPs).
DAG is a physiological activator of protein kinase C [6, 7]
and transcription factor nuclear factor-kB (NF-𝜅B), which
promotes cell survival and proliferation. Diacylglycerol also
interacts indirectly with other signalling molecules such as
small G proteins [8]. IPs are a highly charged family of
lipid-derived metabolites, involved in signal transduction
that results in activation of Akt, mTOR [9], and calcium-
homeostasis [10, 11]; (ii) sphingosine-1-phosphate, a sph-
ingolipid derived from ceramide that is a potent messen-
ger molecule involved in regulating calcium mobilization,
migration, adhesion, and proliferation [12–14]; (iii) the
prostaglandins, which are one type of fatty-acid derived
eicosanoid involved in inflammation [15, 16] and immunity
[17]; (iv) phosphatidylserine, a phospholipid that plays an
important role in a number of signaling pathways, includes
kinases, small GTPases, and fusogenic proteins [18]; (v) the
steroid hormones such as estrogen, testosterone, and cortisol,
which modulate a host of functions such as reproduction,
metabolism, stress response, inflammation, blood pressure,
and salt and water balance [19].
2. Lipids Damage by Reactive Oxygen Species
One of the consequences of uncontrolled oxidative stress
(imbalance between the prooxidant and antioxidant levels
in favor of prooxidants) is cells, tissues, and organs injury
caused by oxidative damage. It has long been recognized that
high levels of free radicals or reactive oxygen species (ROS)
can inflict direct damage to lipids. The primary sources of
endogenous ROS production are the mitochondria, plasma
membrane, endoplasmic reticulum, and peroxisomes [20]
through a variety of mechanisms including enzymatic reac-
tions and/or autooxidation of several compounds, such
as catecholamines and hydroquinone. Different exogenous
stimuli, such as the ionizing radiation, ultraviolet rays,
tobacco smoke, pathogen infections, environmental toxins,
and exposure to herbicide/insecticides, are sources of in vivo
ROS production.
The two most prevalent ROS that can affect profoundly
the lipids are mainly hydroxyl radical (HO∙) and hydroper-
oxyl (HO∙
2
). The hydroxyl radical (HO∙) is a small, highly
mobile, water-soluble, and chemically most reactive species
of activated oxygen. This short-lived molecule can be pro-
duced from O
2
in cell metabolism and under a variety of
stress conditions. A cell produces around 50 hydroxyl radicals
every second. In a full day, each cell would generate 4
million hydroxyl radicals, which can be neutralized or attack
biomolecules [21]. Hydroxyl radicals cause oxidative damage
to cells because they unspecifically attack biomolecules [22]
located less than a few nanometres from its site of generation
and are involved in cellular disorders such as neurodegenera-
tion [23, 24], cardiovascular disease [25], and cancer [26, 27].
It is generally assumed that HO∙ in biological systems is
formed through redox cycling by Fenton reaction, where free
iron (Fe2+) reacts with hydrogen peroxide (H
2
O
2
) and the
Haber-Weiss reaction that results in the production of Fe2+
Haber-Weiss reaction
Fenton reaction
O2
∙OH + H2OH2O2
H+
H+
M(n+1) Mn
O2
∙−
HO∙2
Figure 1: Fenton and Haber-Weiss reaction. Reduced form of
transition-metals (M𝑛) reacts trough the Fenton reaction with
hydrogen peroxide (H
2
O
2
), leading to the generation of ∙OH.
Superoxide radical (O
2
∙−) can also react with oxidized form of
transitionmetals (M(𝑛+1)) in the Haber-Weiss reaction leading to the
production of M𝑛, which then again affects redox cycling.
when superoxide reacts with ferric iron (Fe3+). In addition
to the iron redox cycling described above, also a number of
other transition-metal including Cu, Ni, Co, and V can be
responsible for HO∙ formation in living cells (Figure 1).
The hydroperoxyl radical (HO∙
2
) plays an important
role in the chemistry of lipid peroxidation. This protonated
form of superoxide yields H
2
O
2
which can react with redox
active metals including iron or copper to further generate
HO∙ through Fenton or Haber-Weiss reactions. The HO∙
2
is a much stronger oxidant than superoxide anion-radical
and could initiate the chain oxidation of polyunsaturated
phospholipids, thus leading to impairment of membrane
function [28–30].
2.1. Lipid Peroxidation Process. Lipid peroxidation can be
described generally as a process under which oxidants such
as free radicals or nonradical species attack lipids containing
carbon-carbon double bond(s), especially polyunsaturated
fatty acids (PUFAs) that involve hydrogen abstraction from
a carbon, with oxygen insertion resulting in lipid per-
oxyl radicals and hydroperoxides as described previously
[31]. Glycolipids, phospholipids (PLs), and cholesterol (Ch)
are also well-known targets of damaging and potentially
lethal peroxidative modification. Lipids also can be oxi-
dized by enzymes like lipoxygenases, cyclooxygenases, and
cytochrome P450 (see above, lipid as signaling molecules).
In response to membrane lipid peroxidation, and accord-
ing to specific cellular metabolic circumstances and repair
capacities, the cells may promote cell survival or induce
cell death. Under physiological or low lipid peroxidation
rates (subtoxic conditions), the cells stimulate their mainte-
nance and survival through constitutive antioxidants defense
systems or signaling pathways activation that upregulate
antioxidants proteins resulting in an adaptive stress response.
By contrast, under medium or high lipid peroxidation rates
(toxic conditions) the extent of oxidative damage overwhelms
repair capacity, and the cells induce apoptosis or necrosis
programmed cell death; both processes eventually lead to
molecular cell damage which may facilitate development of
various pathological states and accelerated aging.The impact
of lipids oxidation in cell membrane and how these oxidative
damages are involved in both physiological processes and
major pathological conditions have been analysed in several
reviews [32–35].
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The overall process of lipid peroxidation consists of three
steps: initiation, propagation, and termination [31, 36, 37].
In the lipid peroxidation initiation step, prooxidants like
hydroxyl radical abstract the allylic hydrogen forming the
carbon-centered lipid radical (L∙). In the propagation phase,
lipid radical (L∙) rapidly reacts with oxygen to form a lipid
peroxy radical (LOO∙) which abstracts a hydrogen from
another lipid molecule generating a new L∙ (that continues
the chain reaction) and lipid hydroperoxide (LOOH). In the
termination reaction, antioxidants like vitamin E donate a
hydrogen atom to the LOO∙ species and form a correspond-
ing vitamin E radical that reacts with another LOO∙ forming
nonradical products (Figure 2). Once lipid peroxidation is
initiated, a propagation of chain reactions will take place until
termination products are produced. Review with extensive
information regarding the chemistry associated with each of
these steps is available [31].
2.2. Lipid Peroxidation Products. Lipid peroxidation or reac-
tion of oxygen with unsaturated lipids produces a wide
variety of oxidation products. The main primary products
of lipid peroxidation are lipid hydroperoxides (LOOH).
Among the many different aldehydes which can be formed as
secondary products during lipid peroxidation, malondialde-
hyde (MDA), propanal, hexanal, and 4-hydroxynonenal (4-
HNE) have been extensively studied by Esterbauer and his
colleagues in the 80s [38–49]. MDA appears to be the most
mutagenic product of lipid peroxidation, whereas 4-HNE is
the most toxic [50].
MDAhas beenwidely used formany years as a convenient
biomarker for lipid peroxidation of omega-3 and omega-6
fatty acids because of its facile reaction with thiobarbituric
acid (TBA) [48, 51]. The TBA test is predicated upon the
reactivity of TBA toward MDA to yield an intensely colored
chromogen fluorescent red adduct; this test was first used by
food chemists to evaluate autoxidative degradation of fats and
oils [52]. However, the thiobarbituric acid reacting substances
test (TBARS) is notoriously nonspecific which has led to
substantial controversy over its use for quantification ofMDA
from in vivo samples. Several technologies for the determi-
nation of free and total MDA, such gas chromatography-
mass spectrometry (GC-MS/MS), liquid chromatography-
mass spectrometry (LC-MS/MS), and several derivatization-
based strategies, have been developed during the last decade
[53]. Because MDA is one of the most popular and reliable
markers that determine oxidative stress in clinical situations
[53], and due toMDA’s high reactivity and toxicity underlying
the fact that this molecule is very relevant to biomedical
research community.
4-HNE was first discovered in 60s [54]. Later, in 80s
4-HNE was reported as a cytotoxic product originating
from the peroxidation of liver microsomal lipids [40]. 4-
Hydroxyalkenals produced in the course of biomembrane
lipids peroxidation, elicited either by free radicals or by
chemicals, might exert a genotoxic effect in humans [55].The
4-hydroxyalkenals are the most significant products because
they are produced in relatively large amounts, and they are
very reactive aldehydes that act as “second messengers of
free radicals.” In particular 4-HNE, which has been subjected
to intense scientific scrutiny in 90s [49], is considered
as “one of the major toxic products generated from lipid
peroxides” [49]. 4-HNE high toxicity can be explained by its
rapid reactions with thiols and amino groups [56]. Reactive
aldehydes, especially 4-HNE, act both as signaling molecules
(see below 4-HNE as signaling molecule) and as cytotoxic
products of lipid peroxidation causing long-lasting biological
consequences, in particular by covalent modification of
macromolecules (see below 4-HNE biomolecular adducts).
4-HNE is considered as “second toxic messengers of free
radicals,” and also as “one of the most physiologically active
lipid peroxides,” “one of major generators of oxidative stress,”
“a chemotactic aldehydic end-product of lipid peroxidation,”
and a “major lipid peroxidation product” [57]. Thus, it
is not a surprise that 4-HNE is nowadays considered as
major bioactive marker of lipid peroxidation and a signaling
molecule involved in regulation of several transcription
factors sensible to stress such as nuclear factor erythroid
2-related factor 2 (Nrf2), activating protein-1 (AP-1), NF-
𝜅B, and peroxisome-proliferator-activated receptors (PPAR),
in cell proliferation and/or differentiation, cell survival,
autophagy, senescence, apoptosis, and necrosis (see below 4-
HNE as signaling molecule).
Characteristics of various lipid peroxidation products as
biomarkers have been reviewed on the basis of mechanisms
and dynamics of their formation and metabolism and also
on the methods of measurement, with an emphasis on the
advantages and limitations [58].
2.3. Primary Lipid Peroxidation Product-Lipid Hydroperox-
ides. Hydroperoxides are produced during the propagation
phase constituting the major primary product of lipid perox-
idation process. The hydroperoxide group may be attached
to various lipid structures, for example, free fatty acids, tria-
cylglycerols, phospholipids, and sterols. Lipid hydroperoxide
generation, turnover and effector action in biological systems
have been reviewed [36]. In contrast to free radical, usually
highly reactive and chemically unstable, at moderate reaction
conditions, such as low temperature and absence of metal
ions, lipid hydroperoxides are relativelymore stable products.
We found that lipid hydroperoxides in serum could be useful
to predict the oxidative stress in tissues [59], and the levels
of oxidative stress, including lipid peroxidation, increased
throughout the day [60]. Once formed lipid hydroperoxides
can be target of different reduction reactions, resulting
in peroxidative damage inhibition or peroxidative damage
induction.
Peroxidative Damage Inhibition. Hydroperoxides may
decompose in vivo through two-electron reduction, which
can inhibit the peroxidative damage. The enzymes mainly
responsible for two-electron reduction of hydroperoxides
are selenium-dependent glutathione peroxidases (GPx)
and selenoprotein P (SeP). GPxs are known to catalyze the
reduction of H
2
O
2
or organic hydroperoxides to water or
the corresponding alcohols, respectively, typically using
glutathione (GSH) as reductant. Widely distributed in
4 Oxidative Medicine and Cellular Longevity
OOH
2 3
1
Rearrangement
Unsaturated lipid
Unsaturated lipid
Unsaturated lipid radical
Lipid peroxyl radical
Lipid hydroperoxide
Antioxidant
4
O2
OO∙
R∙ H+
Figure 2: Lipid peroxidation process. In Initiation, prooxidants abstract the allylic hydrogen forming the carbon-centered lipid radical; the
carbon radical tends to be stabilized by a molecular rearrangement to form a conjugated diene (step 1). In the propagation phase, lipid radical
rapidly reacts with oxygen to form a lipid peroxy radical (step 2) which abstracts a hydrogen from another lipid molecule generating a new
lipid radical and lipid hydroperoxide (step 3). In the termination reaction, antioxidants donate a hydrogen atom to the lipid peroxy radical
species resulting in the formation of nonradical products (step 4).
mammalian tissues GPx can be found in the cytosol, nuclei,
and mitochondria [61, 62]. The presence of selenocysteine
(in the catalytic centre of glutathione peroxidases) as the
catalytic moiety was suggested to guarantee a fast reaction
with the hydroperoxide and a fast reducibility by GSH
[61]. SeP is the major selenoprotein in human plasma that
reduced phospholipid hydroperoxide using glutathione or
thioredoxin as cosubstrate. It protected plasma proteins
against peroxynitrite-induced oxidation and nitration or
low-density-lipoproteins (LDL) from peroxidation [62].
Peroxidative Damage Induction. Hydroperoxides may also
decompose in vivo through one-electron reduction and take
part in initiation/propagation steps [31, 36, 37], induce new
lipid hydroperoxides, and feed the lipid peroxidation process;
all these mechanisms can contribute to peroxidative damage
induction/expansion. Lipid hydroperoxides can be converted
to oxygen radicals intermediates such as lipid peroxyl radical
(LOO∙) and/or alkoxyl (LO∙) by redox cycling of transition
metal (M), resulting in lipid hydroperoxide decomposition
and the oxidized or reduced formof thesesmetal, respectively
[63]. The lipid peroxyl and alkoxyl radicals can attack other
lipids promoting the propagation of lipid peroxidation
LOOH +M𝑛 󳨀→ LO∙ +OH− +M𝑛+1 (1)
LOOH +M𝑛+1 󳨀→ LOO∙ +H+ +M𝑛. (2)
Lipid hydroperoxides can also react with peroxynitrite (a
short-lived oxidant species that is a potent inducer of cell
death [64] and is generated in cells or tissues by the reaction
of nitric oxide with superoxide radical) or hypochlorous
acid (a high reactive species produced enzymatically by
myeloperoxidase [65, 66], which utilizes hydrogen peroxide
to convert chloride to hypochlorous acid at sites of inflam-
mation) yielding singlet molecular oxygen [67, 68]. Singlet
oxygen (molecular oxygen in its first excited singlet state 1Δ
𝑔
;
1O
2
)1 can react with amino acid, and proteins resulting in
multiple effects including oxidation of side-chains, backbone
fragmentation, dimerization/aggregation, unfolding or con-
formational changes, enzymatic inactivation, and alterations
in cellular handling and turnover of proteins [69, 70].
Major substrates for lipid peroxidation are polyunsatu-
rated fatty acids (PUFAs) [31, 36, 37], which are a family
of lipids with two or more double bounds, that can be
classified in omega-3 (n-3) and omega-6 (n-6) fatty acids
according to the location of the last double bond relative to
the terminalmethyl end of themolecule.The predominant n-
6 fatty acid is arachidonic acid (AA), which can be reduced (i)
via enzymatic peroxidation to prostaglandins, leukotrienes,
thromboxanes, and other cyclooxygenase, lipoxygenase or
cytochrome P-450 derived products [4]; or (ii) via nonen-
zymatic peroxidation to MDA, 4-HNE, isoprostanes, and
other lipid peroxidation end-products (more stables and toxic
than hydroperoxides) through oxygen radical-dependent
oxidative routes [49, 71]. The continued oxidation of fatty
acid side-chains and released PUFAs, and the fragmentation
of peroxides to produce aldehydes, eventually lead to loss
of membrane integrity by alteration of its fluidity which
finally triggers inactivation of membrane-bound proteins.
Contrary to radicals that attack biomolecules located less
than a few nanometres from its site of generation [22], the
lipid peroxidation-derived aldehydes can easily diffuse across
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membranes and can covalently modify any protein in the
cytoplasm and nucleus, far from their site of origin [72].
2.4. Secondary Lipid Peroxidation Products:MDA. MDA is an
end-product generated by decomposition of arachidonic acid
and larger PUFAs [49], through enzymatic or nonenzymatic
processes (Figure 3). MDA production by enzymatic pro-
cesses is well known but its biological functions and its possi-
ble dose-dependent dual role have not been studied although
MDA is more chemically stable and membrane-permeable
thanROS and less toxic than 4-HNE andmethylglyoxal (MG)
[49]. So far, only few papers have reported that MDA may
act as signaling messenger and regulating gene expression:
(i) very recent research indicated that MDA acted as a
signaling messenger and regulated islet glucose-stimulated
insulin secretion (GSIS) mainly through Wnt pathway. The
moderately high MDA levels (5 and 10 𝜇M) promoted islet
GSIS, elevated ATP/ADP ratio and cytosolic Ca2+ level, and
affected the gene expression and protein/activity production
of the key regulators of GSIS [73]; (ii) in hepatic stellate cells,
MDA induced collagen-gene expression by upregulating
specificity protein-1 (Sp1) gene expression and Sp1 and Sp3
protein levels [74]. Both Sp1 and Sp3 can interact with and
recruit a large number of proteins including the transcrip-
tion initiation complex, histone modifying enzymes, and
chromatin remodeling complexes, which strongly suggest
that Sp1 and Sp3 are important transcription factors in the
remodeling chromatin and the regulation of gene expression
[75]. On the other hand, MDA production by nonenzymatic
processes remains poorly understood despite their potential
therapeutic value, because this MDA is believed to originate
under stress conditions and has high capability of reaction
with multiple biomolecules such as proteins or DNA that
leads to the formation of adducts [76–78], and excessiveMDA
production have been associated with different pathological
states [79–85] (see Table 1). Identifying in vivoMDA produc-
tion and its role in biology is important as indicated by the
extensive literature on the compound (over 15 800 articles in
the PubMed database using the keyword “malondialdehyde
lipid peroxidation” in December 2013).
MDA Production by Enzymatic Processes. MDA can be
generated in vivo as a side product by enzymatic processes
during the biosynthesis of thromboxane A
2
(Figure 3) [86–
90]. TXA
2
is a biologically active metabolite of arachidonic
acid formed by the action of the thromboxane A2 synthase,
on prostaglandin endoperoxide or prostaglandin H2 (PGH
2
)
[4, 91, 92]. PGH
2
previously is generated by the actions of
cyclooxygenases on AA [4, 91, 93].
MDA Production by Nonenzymatic Processes. A mixture of
lipid hydroperoxides is formed during lipid peroxidation
process. The peroxyl radical of the hydroperoxides with a
cis-double bond homoallylic to the peroxyl group permits
their facile cyclization by intramolecular radical addition to
the double bond and the formation of a new radical. The
intermediate free radicals formed after cyclization can cyclize
again to form bicycle endoperoxides, structurally related
to prostaglandins, and undergo cleavage to produce MDA.
Through nonenzymatic oxygen radical-dependent reaction,
AA is the main precursor of bicyclic endoperoxide, which
then undergoes further reactions with or without the partic-
ipation of other compounds to form MDA (Figure 3) [31, 49,
94, 95]. However, it should be possible that other eicosanoids
that can also be generated by nonenzymatic oxygen radical-
dependent reaction [96–99] may be precursor of bicyclic
endoperoxide and MDA. Recent review has addressed the
pathways for the nonenzymatic formation of MDA under
specific conditions [100].
MDA Metabolism. Once formed MDA can be enzymatically
metabolized or can react on cellular and tissular proteins or
DNA to form adducts resulting in biomolecular damages.
Early studies showed that a probable biochemical route
for MDA metabolism involves its oxidation by mitochon-
drial aldehyde dehydrogenase followed by decarboxylation
to produce acetaldehyde, which is oxidized by aldehyde
dehydrogenase to acetate and further to CO
2
and H
2
O
(Figure 3) [49, 101, 102]. On the other hand, phosphoglucose
isomerase is probably responsible for metabolizing cytoplas-
mic MDA to methylglyoxal (MG) and further to D-lactate
by enzymes of the glyoxalase system by using GSH as a
cofactor [103]. A portion of MDA is excreted in the urine as
various enaminals (RNH-CH–CH-CHO) such as N-epsilon-
(2-propenal)lysine, or N-2-(propenal) serine [49].
2.4.1. MDA Biomolecules Adducts. As a bifunctional elec-
trophile aldehyde, MDA reactivity is pH-dependent, which
exists as enolate ion (conjugate bases having a negative
charge on oxygen with adjacent C–C double bond) with low
reactivity at physiological pH. When pH decreases MDA
exists as beta-hydroxyacrolein and its reactivity increases
[49]. MDA’s high reactivity is mainly based on its elec-
trophilicity making it strongly reactive toward nucleophiles,
such as basic amino acid residues (i.e., lysine, histidine, or
arginine). Initial reactions between MDA and free amino
acids or protein generate Schiff-base adducts [49, 104, 175].
These adducts are also referred to as advanced lipid per-
oxidation end-products (ALEs). Acetaldehyde (product of
MDAmetabolism) under oxidative stress and in the presence
of MDA further generates malondialdehyde acetaldehyde
(MAA) adducts [157, 176]. MAA adducts are shown to be
highly immunogenic [177–181].MDAadducts are biologically
important because they can participate in secondary delete-
rious reactions (e.g., crosslinking) by promoting intramolec-
ular or intermolecular protein/DNA crosslinking that may
induce profound alteration in the biochemical properties of
biomolecules and accumulate during aging and in chronic
diseases [72, 104, 182, 183]. Important proteins that can be
modified by MDA adducts are as follows: (i) eElongation
factor 2 (eEF2) catalyzes themovement of the ribosome along
the mRNA in protein synthesis. MDA adducts with eEF2
could contribute to decline of protein synthesis, secondary to
LP increase (see below—cumene hydroperoxide-induced lipid
peroxidation); (ii) factor H (FH) is the main regulator of the
alternative pathway in plasma that tightly controls the activa-
tion of complement to prevent attack against host cells. MDA
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Table 1: Common pathological processes linked to MDA and 4-HNE.
Pathological processes Aldehyde References
Alzheimer’s disease MDA4-HNE
[104–113]
[81, 108, 114–121]
Cancer MDA4-HNE
[109, 122–130]
[72, 126–128, 131–136]
Cardiovascular diseases MDA4-HNE
[72, 79, 109, 123, 135, 137–141]
[72, 104, 109, 131, 135, 138, 139, 142–144]
Diabetes MDA4-HNE
[79, 109, 123, 140, 145–150]
[131, 135, 142, 143, 151–156]
Liver disease MDA4-HNE
[123, 135, 157–164]
[135, 160–163, 165–169]
Parkinson’s disease MDA4-HNE
[81, 108, 114–121]
[72, 114, 131, 135, 142, 170–174]
PUFA
AA
Oxy radical Lipid hydroperoxide
Bicyclic
endoperoxide
Monocyclic
peroxide
HHT
MDA
Malonic
semialdehyde
MDA-protein adducts
MDA-DNA adducts
AcetaldehydeAcetateAcetyl
CoA
Biomolecular damage
cell death
1
2
3 33
4
5
46
7
Cyclization
CO2 + H2O
O2
O2
+ H+
H+
H+
PUFA peroxide-
radical∙
Radical∙
PUFA-radical∙
2O2
PGG2
PGH2
TXA2
Figure 3: MDA formation and metabolism. MDA can be generated in vivo by decomposition of arachidonic acid (AA) and larger PUFAs
as a side product by enzymatic processes during the biosynthesis of thromboxane A
2
(TXA
2
) and 12-l-hydroxy-5,8,10-heptadecatrienoic acid
(HHT) (blue pathway), or through nonenzymatic processes by bicyclic endoperoxides produced during lipid peroxidation (red pathway).
One formed MDA can be enzymatically metabolized (green pathway). Key enzymes involved in the formation and metabolism of MDA:
cyclooxygenases (1), prostacyclin hydroperoxidase (2), thromboxane synthase (3), aldehyde dehydrogenase (4), decarboxylase (5), acetyl
CoA synthase (6), and tricarboxylic acid cycle (7).
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adducts with FH can block both the uptake ofMDA-modified
proteins by macrophages and MDA-induced proinflamma-
tory effects in vivo in mice [184]; MDA adducts or MAA
adducts can promote binding of complement; (iii) anaphyla-
toxin C3a (proinflammatory complement components) with
oxidatively modified low-density lipoproteins (Ox-LDL) and
contributes to inflammatory processes involving activation
of the complement system in atherosclerosis [185]; and (iv)
protein kinase C (PKC) is known to play a major role in
intracellular signal transduction affecting such processes as
proliferation, differentiation, migration, inflammation, and
cytoskeletal organization. BSA-MAA induces the activation
of a specific isoform of PKC, PKC-𝛼, in hepatic stellate cells
(HSCs) and induces the increased secretion of urokinase-
type plasminogen activator, a key component of the plasmin-
generating system, thereby contributing to the progression
of hepatic fibrosis [186]. A recent review shows a list of up
to thirty-three proteins known to be modified by MDA and
including enzymatic proteins, carrier proteins, cytoskeletal
proteins, and mitochondrial and antioxidant proteins [76].
It has also been proposed that MDA could react phys-
iologically with several nucleosides (deoxy-guanosine and
cytidine) to form adducts to deoxyguanosine and deoxya-
denosine, and the major product resulting is a pyrimidop-
urinone called pyrimido[1,2-a]purin-10(3H-)one (M1G or
M1dG) [122, 123, 187, 188]. MDA is an important contributor
to DNA damage and mutation [122, 124]. The main route for
repair of M1dG residues in genomic DNA appears to be the
nucleotide excision repair (NER) pathway [188, 189]. In the
absence of repair, MDA-DNA adducts may lead to mutations
(point and frameshift) [124], strand breaks [122, 190], cell
cycle arrest [191], and induction of apoptosis [192]. M1dG is
oxidized to 6-oxo-M1dG in rats and that xanthine oxidase
(XO) and aldehyde oxidase (AO) are the likely enzymes
responsible [193]. This MDA-induced DNA alteration may
contribute significantly to cancer and other genetic diseases.
Hypermethylated in cancer 1 (HIC1) is a tumor suppressor
gene that cooperates with p53 to suppress cancer develop-
ment. New funding has shown that highest HIC1methylation
levels in tobacco smokers were significantly correlated with
oxidative DNA adducts M1dG [125]. Research also suggests
that persistent M1dG adducts in mitochondrial DNA hinder
the transcription ofmitochondrial genes [194]. Dietary intake
of certain antioxidants such as vitamins was associated with
reduced levels of markers of DNA oxidation (M1dG and 8-
oxodG) measured in peripheral white blood cells of healthy
subjects, which could contribute to the protective role of
vitamins on cancer risk [195].
2.5. Secondary Lipid Peroxidation Products: 4-HNE. 4-
Hydroxynonenal (4-HNE), 𝛼, 𝛽-unsaturated electrophilic
compounds, is the major type of 4-hydroxyalkenals end-
product, generated by decomposition of arachidonic acid and
larger PUFAs, through enzymatic or nonenzymatic processes
[49]. 4-HNE is an extraordinarily reactive compound con-
taining three functional groups: (i) C=C double bond that
can be target to Michael additions to thiol, reduction or
epoxidation, (ii) carbonyl group which can yield acetal/thio
acetal or can be target to Schiff-base formation, oxidation, or
reduction, and (iii) hydroxyl group which can be oxidized to
a ketone [56].
4-HNE is the most intensively studied lipid peroxidation
end-product, in relation not only to its physiological and
protective function as signaling molecule stimulating gene
expression, but also to its cytotoxic role inhibiting gene
expression and promoting the development and progression
of different pathological states. In the last three years,
excellent reviews have been published summarizing both
signaling and cytotoxic effects of this molecule in biology, for
example, overview of mechanisms of 4-HNE formation and
most common methods for detecting and analyzing 4-HNE
and its protein adducts [196]. Review focuses on membrane
proteins affected by lipid peroxidation-derived aldehydes,
under physiological and pathological conditions [131].
Jaganjac andCo-workers have described the role of 4-HNE as
second messengers of free radicals that act both as signaling
molecules and as cytotoxic products of lipid peroxidation
involvement in the pathogenesis of diabetes mellitus (DM)
[151]. Chapple and Co-workers summarized the production,
metabolism and consequences of 4-HNE synthesis within
vascular endothelial, smooth muscle cells and targeted
signaling within vasculature [142]. Review focuses on the role
of 4-HNE and Ox-PLs affecting cell signaling pathways and
endothelial barrier dysfunction through modulation of the
activities of proteins/enzymes byMichael adducts formation,
enhancing the level of protein tyrosine phosphorylation of
the target proteins, and by reorganization of cytoskeletal,
focal adhesion, and adherens junction proteins [197]. An
overview of molecular mechanisms responsible for the
overall chemopreventive effects of sulforaphane (SFN),
focusing on the role of 4-HNE in these mechanisms,
which may also contribute to its selective cytotoxicity to
cancer cells [198]. Perluigi and Co-workers summarized the
role of lipid peroxidation, particularly of 4-HNE-induced
protein modification, in neurodegenerative diseases.
In this review, the authors also discuss the hypothesis
that altered energy metabolism, reduced antioxidant
defense, and mitochondrial dysfunction are characteristic
hallmarks of neurodegenerative [170]. Zimniak described
the effects of 4-HNE and other endogenous electrophiles on
longevity, and its possible molecular mechanisms. The role
of electrophiles is discussed, both as destabilizing factors
and as signals that induce protective responses [199]. Reed
showed the relationship between lipid peroxidation/4-
HNE and neurodegenerative diseases. It also demonstrates
how findings in current research support the common
themes of altered energy metabolism and mitochondrial
dysfunction in neurodegenerative disorders [171]. Fritz
and Petersen summarized the generation of reactive
aldehydes via lipid peroxidation resulting in protein
carbonylation, and pathophysiologic factors associated with
4-HNE-protein modification. Additionally, an overview
of in vitro and in vivo model systems used to study the
physiologic impact of protein carbonylation, and an update
of the methods commonly used in characterizing protein
modification by reactive aldehydes [200]. Butterfield and Co-
workers showed that several important irreversible protein
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modifications including protein nitration and 4-HNE
modification, both which have been extensively investigated
in research on the progression of Alzheimer’s disease (AD)
[201]. Balogh and Atkins described the cellular effects
of 4-HNE, followed by a review of its GST-catalyzed
detoxification, with an emphasis on the structural attributes
that play an important role in the interactions with alpha-
class GSTs. Additionally, a summary of the literature that
examines the interplay between GSTs and 4-HNE in model
systems relevant to oxidative stress is also discussed to
demonstrate the magnitude of importance of GSTs in the
overall detoxification scheme [202]. Like MDA, 4-HNE has
high capability of reaction with multiple biomolecules such
as proteins or DNA that lead to the formation of adducts
[49].
4-HNE Production by Enzymatic Processes. 4-HNE is a
lipid peroxidation end-product of enzymatic transforma-
tion of n-6 PUFAs (AA, linoleic acid, and other) by 15-
lipoxygenases (15-LOX). Two different 15-LOX exist, (i)
15-LOX-1 (reticulocyte type) expressed in reticulocytes,
eosinophils, and macrophages; (ii) and 15-LOX-2 (epidermis
type) expressed in skin, cornea, prostate, lung, and esophagus
[203–205]. Mice do not express 15-LOX and only express
the leukocyte-derived 12-LOX. In plant enzymatic route
to 4-HNE includes lipoxygenase (LOX), -hydroperoxide
lyase (HPL), alkenal oxygenase (AKO), and peroxygenases
(Figure 4) [206]. The main precursors of 4-HNE in human
are 13-hydroperoxyoctadecadienoic acid (13-HPODE) pro-
duced by the oxidation of linoleic acid by 15-LOX-1 [207] and
15- hydroperoxyeicosatetraenoic acids (15-HPETE) produced
by the oxidation of AA by 15-LOX-2 [208].These compounds
are short lived and are catabolised into various families
of more stable compounds such as 15-HETEs, lipoxins,
and leukotrienes [4]. 15-HPETE is associated with anti-
inflammatory and proapoptotic functions (the release of
cytochrome c, activation of caspase-3 and 8, PARP, and Bid
cleavage) and DNA fragmentation [209, 210].
4-HNE Production by Nonenzymatic Processes. 4-HNE can
be formed through several nonenzymatic oxygen radical-
dependent routes involving the formation of hydroperoxides,
alkoxyl radicals, epoxides, and fatty acyl crosslinking reac-
tions. Spickett C [196] recently reviewed the mechanisms of
formation of 4-HNE during lipid peroxidation and showed
that the main processes leading to 4-HNE are likely beta-
cleavage reaction of lipid alkoxy-radicals, which can be
summarized into five generic mechanisms: (i) reduction of
the hydroperoxide to a lipid alkoxy radical by transitionmetal
ions, such as Fe2+ followed by b-scission; (ii) protonation of
the lipid hydroperoxide yields an acidified lipid hydroperox-
ide that undergoes Hock rearrangement of a C–C to C–O
bond followed by hydrolysis and Hock cleavage; (iii) the lipid
peroxyl radical of the hydroperoxides permits their facile
cyclization to dioxetane and ending with dioxetane cleavage;
(iv) free radical attack to 𝜔-6 PUFA on bis-allyl site yielding
a free radical intermediate, that further reacts with molecular
oxygen to generate hydroperoxide derivatives such as 13-
HPODE or 15-HPETE.The abstraction of an allylic hydrogen
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Figure 4: Enzymatic production of 4-HNE and metabolism. In
plant enzymatic route to 4-HNE includes lipoxygenase (LOX),
-hydroperoxide lyase (HPL), alkenal oxygenase (AKO), and per-
oxygenases. 4-HNE metabolism may lead to the formation of
corresponding alcohol 1,4-dihydroxy-2-nonene (DHN), corre-
sponding acid 4-hydroxy-2-nonenoic acid (HNA), and HNE–
glutathione conjugate products. 4-HNE conjugation with glu-
tathione s-transferase (GSH) produce glutathionyl-HNE (GS-HNE)
followed by NADH-dependent alcohol dehydrogenase (ADH-
)catalysed reduction to glutathionyl-DNH (GS-DNH) and/or alde-
hyde dehydrogenase (ALDH-)catalysed oxidation to glutathionyl-
HNA (GS-HNA). 4-HNE is metabolized by ALDH yielding HNA,
which is metabolized by cytochrome P450 (CYP) to form 9-
hydroxy-HNA (9-OH-HNA). 4-HNE may be also metabolized by
ADH to produce DNH.
of their structure produce another radical intermediate that
after oxygenation step forms the corresponding dihydroper-
oxyde derivative (unstable), which after Hock rearrange-
ment and cleavage produces 4-hydroperoxy-2E-nonenal (4S-
HPNE), immediate precursor of HNE; and (v) the oxida-
tion products generated after reaction of linoleate-derived
hydroperoxy epoxide (13-Hp-Epo-Acid) with Fe+2 yields an
alkolxyl radical, which undergo to di-epoxy-carbinyl radical
and after beta-scission yield different aldehydes compounds
including 4-HNE (Figure 5).
Once formed 4-HNE, and depending of cell type and
cellular metabolic circumstances can promote cell survival or
death. Cells expressing differentiated functions representative
for the in vivo situation react more sensitively to 4-HNE than
cell lines.The different response with respect to the endpoints
of genotoxicity probably depends on the different metabo-
lizing capacities and thus the action of different metabolites
of 4-HNE [211]. 4-HNE can be enzymatically metabolized
at physiological level and cells can survive; 4-HNE can play
an important role as signaling molecule stimulating gene
expression (mainly Nrf2) with protective functions that can
enhance cellular antioxidant capacity and exert adaptive
response when 4-HNE level is low; under this circumstances
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Figure 5: Nonenzymatic 4-HNE production. Initial abstraction of bisallylic hydrogen of lipoic acid (LA) produces fatty radicals. 4-HNE
formation starting with 9- and 13-hydroperoxyoctadecadienoate (HPODE) (red and blue pathways, resp.). 4-HNE is generated by beta-
scission of a hydroxyalkoxy radical that is produced after cyclization of alkoxy radical in the presence of transition metal ions and two
molecules of oxygen; this reaction involves hydrogen abstraction (1). Peroxy radical cyclizes to form a dioxetane which is oxygenated
to peroxy-dioxetane that is fragmented and after two hydrogen abstractions produce 4-HNE (2). Hydroperoxyl radical is oxygenated to
dioxetane that is further fragmented to produce 4-hydroperoxy-2E-nonenal (4-HPNE), an immediate precursor of 4-HNE (3). Bicyclic
endoperoxides react with reduced form of transition metal, such as iron (Fe2+) to produce alkoxyl radicals which after reaction with oxygen
(O
2
), hydrogen abstraction (H+), and fragmentation produce 4-HNE (4). Alkoxyl radical after cyclization, oxygenation, hydrogen abstraction,
oxidation of transitionmetal, hydrolysis, and rearrangement yields 4-HNE (5).With arachidonic acid, 11- and 15- hydroperoxyeicosatetraenoic
acids (HPETE) are the precursors to form 4-HNE via the analogous mechanisms.
cells can survive; 4-HNE can promote organelle and protein
damage leading to induction of autophagy, senescence, or cell
cycle arrest at 4-HNEmedium level and cells can subsist; and
finally 4-HNE induces apoptosis or necrosis programmed
cell death at 4-HNE high or very high level, respectively,
and cells die. These processes eventually lead to molecular
cell damage which may facilitate development of various
pathological states. High levels of 4-HNE can also react with
proteins and/or DNA to form adducts resulting in a variety
of cytotoxic and genotoxic consequences (Figure 6).
4-HNE Metabolism. The main goal of the rapid intracellular
metabolism of 4-HNE in mammalian cells is to protect
proteins from modification by aldehydic lipid peroxida-
tion products [212]. The biochemical routes of 4-HNE
metabolism that lead to the formation of corresponding
alcohol 1,4-dihydroxy-2-nonene (DHN), corresponding acid
4-hydroxy-2-nonenoic acid (HNA), and HNE-glutathione
conjugate products can be summarized according to stress
levels: (i) under physiological or low stress levels the major
4-HNE detoxification step is conjugation with GSH to yield
glutathionyl-HNE (GS-HNE) or glutathionyl-lactone (GS-
)lactone (cyclic ester 4-HNE- form) followed by NADH-
dependent alcohol dehydrogenase (ADH-)catalysed reduc-
tion to glutathionyl-DNH (GS-DNH) and/or aldehyde dehy-
drogenase (ALDH-)catalysed oxidation to glutathionyl-HNA
(GS-HNA); (ii) at moderate stress levels, 4-HNE undergoes
aldehyde dehydrogenase (ALDH-)catalysed oxidation yield-
ing HNA, that may be further metabolized in mitochondria
through beta-oxidation by cytochrome P450 to form 9-
hydroxy-HNA; and (iii) at high stress levels, 4-HNE is
metabolized byADH (that belongs to the aldo-keto reductase
(AKR) superfamily) to produce DNH [131, 196, 202, 212, 213]
(Figure 4). By disrupting the Gsta4 gene that encodes the
alpha class glutathione s-transferase (GST) isozyme GSTA4-
4 in mice showed that GSTA4-4 plays a major role in
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Figure 6: 4-HNE promotes cell survival or induces cell death. Depending on cell type, damage/repair capacities and cellular metabolic
circumstances 4-HNE can promote cell survival or induce cell death. 4-HNE at physiological levels is enzymatically metabolized and at low
levels plays an important role as signaling molecule stimulating gene expression, enhance cellular antioxidant capacity and exert adaptive
response; at medium levels organelle and protein damage lead to induction of autophagy, senescence, or cell cycle arrest and at high or very
high levels promote adducts formation and apoptosis or necrosis cell death, respectively.
protecting cells from the toxic effects of oxidant chemicals by
attenuating the accumulation of 4-HNE [214]. Overexpres-
sion and inhibition of ALDH activity reduce and increase,
respectively, the 4-HNE toxicity and 4-HNE-protein adducts
levels in cell culture [215, 216].
2.5.1. 4-HNE as Signaling Molecule. At moderate concentra-
tion, when the basal level of antioxidant enzymes cannot
be sufficient to neutralize 4-HNE, cells can survive due to
4-HNE may regulate several transcription factors sensible
to stress such as nuclear factor erythroid 2-related factor 2
(Nrf2), activating protein-1 (AP-1), NF-𝜅B, and peroxisome-
proliferator-activated receptors (PPAR). It also activates
stress response pathways such as mitogen-activated protein
kinases (MAPK), EGFR/Akt pathways, and protein kinase
C. Different labs demonstrated the 4-HNE-dependent induc-
tion of Nrf2, a primary sensor and oxidative stress regulator
[217–221]. Also administration of the Nrf2-ARE activators
protect from 4-HNE toxicity [222]. Under physiological con-
ditions, Nrf2 is sequestered in the cytoplasm by the repressor
protein Keap1, but in response to oxidant stimuli Nrf2 is
activated and translocated into the nucleus wheremediate the
transcription of antioxidant/cytoprotective genes by binding
to the antioxidant-response element (ARE) within DNA
[223]. The Nrf2-ARE pathway has essential role in different
pathological states such as neurodegenerative diseases [223],
cancer [224], diabetes [225], and infectious disease [226].The
main genes regulated by 4-HNE- inducedNrf2-ARE pathway
are as follows: (i) HO-1, an antioxidant protein that catalyzes
the degradation of heme to biliverdin, which is then degraded
to bilirubin; both biliverdin and bilirubin have antioxidant
properties [227]; 4-HNE can upregulate HO-1 [217, 220, 221,
228–230]; (ii) thioredoxin (Trx) and thioredoxin reductase
(TrxR); Trx is a small (13 kDa) antioxidant ubiquitous protein
with two redox-active cysteine residues (-Cys-Gly-Pro-Cys-)
in its active center; oxidized Trx is reduced back to the
active form of Trx by Trx reductase (TrxR) in the presence
of NADPH [231]; 4-HNE can upregulate Trx/TrxR [220,
221, 232]; (iii) glutamate cystein ligase (GCL) is a major
determinant enzyme inGSH synthesis [233, 234]. 4-HNE can
upregulate GCL [235–239].
Involvement of AP-1 transcription factor in 4-HNE-
induced cell signaling has been demonstrated by several
studies which showed an AP-1 upregulation by 4-HNE [240–
243]. Activation of AP-1 binding may lead to the 4-HNE-
induced increase in GSH content [239]. AP-1 is a dimer con-
sisting of basic region-leucine zipper proteins from the Jun
and Fos subfamilies. AP-1 transcription factors control cell
proliferation, survival, and death. Growth factors, cytokines,
cellular stress, and many other stimuli activate AP-1 [244,
245].
NF-𝜅B is a dimeric transcription factor that regulates
diverse biological processes, including immune responses,
inflammation, cell proliferation, and apoptosis. The NF-
𝜅B protein complex is retained in an inactive state in the
cytoplasm by binding to inhibitory proteins I𝜅Bs family
[246]. Various cellular stimuli, such as oxidative stress, I𝜅Bs
are phosphorylated, making them susceptible to degradation
by the ubiquitin-proteasome system. This results in nuclear
translocation of NF-𝜅B complex where it can bind to various
promoter areas of its target genes and induce gene tran-
scription of the corresponding genes [246, 247], most of
which are implicated in the regulation of inflammation. 4-
HNE can activate or inhibit NF-𝜅B depending on the type
of cells used. For example, 4-HNE inhibited the activity of
NF-𝜅B in hepatocytes [165], cortical neurons [248], ARPE-
19 human retinal pigment epithelial cells [249], Kupffer
cells [250], human aortic endothelial cells [251], human
colorectal carcinoma, and lung carcinoma cell [252]. On the
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contrary, 4-HNE induced activity of NF-𝜅B in macrophages
[253], vascular smooth muscle cells [254], PC12 cells [255],
optic nerve head astrocytes [256], human osteoarthritic
chondrocytes [257], human fibroblasts [258], and human
monocytic lineage cells [259].
PPARs comprise three subtypes (PPAR𝛼, 𝛽/𝛿, and 𝛾)
to form a nuclear receptor superfamily. PPARs act as key
transcriptional regulators of lipidmetabolism,mitochondrial
biogenesis, and antioxidant defense [260, 261]. PPARs inter-
action/modulation with 4-HNE has been reviewed [262].
4-HNE increased PPAR-𝛾 gene expression and accelerated
adiponectin protein degradation in adipocytes [263]; expres-
sion of PPAR-𝛾 was induced in HL-60 and U937 cells by
4-HNE treatment [264], whereas in the colon cancer cell
(CaCo-2) PPAR𝛾 protein expression was not induced after 4-
HNE treatment [265]; 4-HNE increased PPAR𝛾2 expression
in C2C12 cells [266]. PPAR-𝛽/𝛿 is activated by 4-HNE in 3T3-
L1 preadipocytes cells [267]. 4-HNE activates PPAR-𝛿 and
amplifies insulin secretion in INS-1E 𝛽-cells [152].
MAP kinases family can be activated in response to
diverse stimuli such as oxidative stress, lipopolysaccharides,
inflammatory cytokines, growth factors, or endoplasmic
reticulum (ER) stress and are involved in several cellu-
lar responses like cell proliferation and/or differentiation,
inflammation, proteasomal-mediated protein degradation,
and apoptosis. Members of the major mitogen-activated
protein kinase (MAPK) subfamilies are the extracellular
signal-regulated kinase (ERK), p38, and Jun N-terminal
kinase (JNK) subfamilies. The mechanism by which MAPK
signaling cascades are activated by 4-HNE is not well known.
For example, activation of different MAPK under various
stimuli can affect both apoptotic and prosurvival signaling.
In corneal epithelial cells, 4-HNE caused a time-dependent
induction of HO-1 mRNA and protein via modification
and activation of Erk1/2, JNK and p38 MAP kinases, as
well as phosphoinositide-3-kinase (PI3)/Akt. Inhibition of
p38 blocked 4-HNE-induced HO-1 expression; inhibition of
Erk1/2 and, to a lesser extent, JNK and PI3K/Akt suppressed
4-HNE-induced HO-1 [268]. 4-HNE also stimulated Erk1/2,
JNK, p38, and PI3 kinase in keratinocyte, and the inhibitors
of these enzymes suppressed 4-HNE-induced expression of
HO-1 [269]. In PC12 cells, 4-HNE treatment induced ERK,
JNK, and p38 MAPK activation as well as induced the
expression of HO-1. Addition of p38MAPK specific inhibitor
SB203580 attenuated HO-1 upregulation; these results indi-
cate that 4-HNE-induced transient p38 MAPK activation
may serve as an upstream negative regulator of ER stress
and confer adaptive cytoprotection against 4-HNE-mediated
cell injury [228]. In rat liver epithelial RL34 cells, 4-HNE
upregulates the cyclooxygenase-2 (COX-2, which plays a key
role in conversion of free arachidonic acid to PGs) expression
by the stabilization of COX-2 mRNA via activation of the
p38 MAPK pathway [270]. In human hepatic stellate cells
(hHSC), 4-HNE forms adducts with JNK and this event
leads to JNK nuclear translocation and activation as well
as to c-jun and AP-1 induction [271]. In human bronchial
epithelial cells, 4-HNE downmodulates the protein-tyrosine
phosphatase SH2 domain containing phosphatase-1 (SHP-1)
which negatively regulates JNK activity [272].We can also see
the protective effects of MAPK activation via GSH induction
because the activation of the ERK pathway is involved inGCL
(the rate-limiting enzyme in de novo glutathione (GSH)
synthesis) regulation in rat cells [273] while the JNKpathways
appear to be involved in human HBE-1 cells [274].
In human monocytes, 4-HNE was shown to significantly
inhibit p38 and ERK activity, which resulted in inhibition of
TNF and interleukin-1beta production in response to LPS.
The data suggest that 4-HNE, at nontoxic concentrations, has
anti-inflammatory properties [275]. In human osteoarthritic
osteoblasts, 4-HNE also showed a significant (approximately
70%) decrease of TNF-𝛼-induced IL-6 mRNA expression via
the NF-𝜅B signaling pathway. However, only p38 MAPK and
JNK1/2 were activated, but not ERK1/2 [276], while 4-HNE
also inducedCOX-2 expression and prostaglandin E2 (PGE2)
release [257, 276].
On the other hand, 4-HNE mediated depletion of intra-
cellular thiols, protein tyrosine phosphorylation, MAPK
(JNK, ERK, and p38) activation, and modulates integrin
resulting in reorganization of cytoskeletal, focal adhesion
proteins, and barrier dysfunction in lung microvascular
endothelial cells [277]. Results suggest that activation and
phosphorylation of MAP kinases (JNK, ERK, and p38) play
an important role in 4-HNE mediated toxicity and cell
death in mouse embryonic fibroblasts (MEF), and absence
of GSTA4–4 potentiates the cytotoxic effects of 4-HNE. The
increase of apoptosis in Gsta4 null MEF by 4-HNE was asso-
ciated with the enhanced accumulation of 4-HNE-protein
adducts, DNA damage, and the activation of caspases-3,
-8, and -9 [214]. 4-HNE upregulates and phosphorylates
cytosolic phospholipase A-2 (cPLA-2) in cultured microglial
cell line (Ra2) via the ERK and p38 MAPK pathways [278].
cPLA is a proinflammatory enzyme that stimulateAA- release
by hydrolyzes glycerophospholipids with AA in the sn-2
position.
Matrix metalloproteinases (MMPs) constitute a large
group of endoproteases that are not only able to cleave all
protein components of the extracellular matrix but also to
activate or inactivate many other signaling molecules, such
as receptors, adhesion molecules, and growth factors [279].
4-HNE induced MMP-9 production in macrophages [280]
and MMP-2 in vascular smooth muscle cells (VSMC) [281]
via activation of ERK and p38MAPKpathways, consequently
leading to plaque instability in atherosclerosis. 4-HNE also
enhances MMP-2 production in VSMC via mitochondrial
ROS-mediated activation of the Akt/NF-kappaB signaling
pathways [254]. In osteoarthritic (OA) synovial cells, 4-HNE
induced MMP-13 mainly through activation of p38 MAPK
[282].
Akt (a.k.a protein kinase B or PKB) comprises three closely
related isoforms Akt1, Akt2, and Akt3 (or PKB𝛼/𝛽/𝛾 resp.),
which play a role in the regulation of cell proliferation,
survival, and metabolism. Dysregulation of Akt leads to
diseases such as cancer, diabetes, and cardiovascular and
neurological diseases [283]. Under conditions of enhanced
oxidative stress, a major cellular response is the activa-
tion of the Akt pathway that involves the oxidation and
subsequent inactivation of PTEN (phosphatase and tensin
homolog deleted on chromosome 10), a tumor suppressor
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and primary regulator of Akt [284]. Recent studies have
also demonstrated that activation of PI3 K/Akt signaling by
4-HNE occurs via modification and inhibition of PTEN,
a regulatory protein that suppresses Akt2 activity, which
is selectively phosphorylated by 4-HNE in both cellular
human hepatocellular carcinoma cell line (HepG2) [285]
and animal models (ethanol-fed mice) [286]. In HepG2
cells, 4-HNE inhibits H
2
O
2
-mediated activation of the Akt
pathway in leading to phosphorylation of Akt1 but not Akt2,
decreased cell proliferation, and decreased expression of
cyclin D1 [287]. In retinal pigment epithelial (RPE) cells, at
lower concentrations 4-HNE triggered phosphorylation of
epidermal growth factor receptor (EGFR) and activation of its
downstream signaling components ERK1/2 and Akt; this led
to protective mechanism against oxidative stress [288]. Akt-
induced activity by 4-HNE promotes cell survival through
induction of HO-1 mRNA and protein in corneal epithelial
cells [268], and in keratinocyte [269]. The inhibitors of Akt
suppressed 4-HNE-induced expression of HO-1.
Protein kinases C (PKCs) are a family of multifunctional
enzymes that play crucial roles in the transduction of many
cellular signals such as control of cell proliferation, survival,
and transformation by phosphorylating various targets. The
PKC family consists of three different groups: conventional
(𝛼, 𝛽1, 𝛽2, and 𝛾), novel (𝛿, 𝜀, 𝜂, and 𝜃), and atypical (𝜁
and 𝜆/𝜏). Conventional and novel PKC isoforms are lipid-
sensitive enzymes and calcium-dependent and are usually
activated by growth factors through stimulation of phos-
pholipase C (PLC) which hydrolyzes phosphatidylinositol-
4,5-bisphosphate (PIP2) to generate inositol triphosphate
(IP3) and DAG [6, 289]. Cells can express more than one
PKC isoform, and individual PKCs can mediate different
biological processes. For example, in human promyelo-
cytic leukemia (HL-60) cells [290–292] and rat neutrophils
[293] 4-HNE induced a significant increase of PLC activity,
which should result in an increased production of IP3 and
DAG, known to stimulate PKC [289]. Phagocytes, such
as granulocytes and monocytes/macrophages which engulf
microbial intruders and effectively kill and eradicate the
foreign bodies, contain a membrane-associated NADPH
oxidase that produces superoxide leading to other ROS with
microbicidal, tumoricidal, and inflammatory activities [294].
In RAW 264.7 mouse macrophage cells, 4-HNE exhibited
a concentration-dependent inhibition of ROS by adduction
to PKC, a protein vital in the assembly and activation of
NADPH oxidase [295]. In rat hepatocyte PKC- isoforms
activity is differentially regulated by concentrations 4-HNE.
For example, PKC-𝛼 activity was decreased in a dose-
dependentmanner by all concentrations of 4-HNE, while low
concentrations of 4-HNE increased PKC 𝛽I and, to a much
greater extent, PKC𝛽II activities. By contrast, theywere unaf-
fected or even inhibited by higher concentrations of 4-HNE.
This PKC-dependent- 4-HNE regulation could be involved
in the traffic of secretory glycoproteins [296]. In NT2 neu-
rons, low 4-HNE concentrations (similar to concentrations
detected in AD brain tissue) induced a 2–6 fold increase
of intracellular amyloid 𝛽-protein (A𝛽) production that
was concomitant with selective activation of 𝛽I and 𝛽II
PKC isoforms [297, 298]. In macrophages, a marked and
early upregulation of monocyte chemoattractant protein 1
(MCP-1) release occurs in response to low 4-HNE concen-
trations, most likely through of the increase in the activity
of PKC-𝛽I and 𝛽II classic isoforms, while the activation of
PKC-𝛿 appeared to be involved in LPS-stimulated cells [299].
Treatment of macrophages with 4-HNE, cell-permeable
esters of glutathionyl-4-hydroxynonenal (GS-HNE) and
glutathionyl-1,4-dihydroxynonane (GS-DHN) activated NF-
𝜅B and PLC/PKC. Aldolase reductase catalyzes the reduction
of GS-HNE to GS-DHN. AR inhibition/ablation prevented
PLC, PKC, and IKKalpha/beta, and NF-𝜅B activation caused
by 4-HNE and GS-HNE, but not by GS-DHN, suggests a
novel role for a reduced glutathione-lipid aldehyde conjugate
(such asGS-DHN) as an obligatorymediator of ROS-induced
cytotoxicity [300].
2.5.2. Effect of 4-HNE on Autophagy. One of the most impor-
tant processes for maintaining normal metabolic and redox
signaling, through degradation of damaged proteins and
organelles, is autophagy-lysosomal pathway [301]. 4-HNE
can promote protein-adducts leading to protein damage and
to induction of autophagy-lysosomal pathway [302], a pro-
cess that is increased by treatmentwith an autophagy stimula-
tor, rapamycin. If autophagy is blocked with a PI3 K inhibitor,
3-methyladenine, apoptotic cell death occurs [301, 302]. Sev-
eral mechanisms by which 4-HNE induces autophagy have
been reported. For example, 4-HNE promotes the formation
of protein adducts that accumulate in the endoplasmic
reticulum (ER) and led to autophagy in rat aortic smooth
muscle cells, through selective activation of the PKR-like ER
kinase (PERK) pathway accompanied by JNK activation, the
upregulation of the HO-1, increased microtubule-associated
protein 1 light chain 3 (LC3) formation, and maintenance of
cell viability under conditions of excessive 4-HNE-protein
adducts accumulation [303]. In differentiated SH-SY5Y neu-
roblastoma cells, glucose-dependent autophagy serves as a
protective mechanism in response to 4-HNE because low
4-HNE-concentrations increased autophagy and induced
concentration dependent CASP3/caspase-3 activation and
cell death. Additionally inhibition of glucose metabolism by
2-deoxyglucose and glycolysis by koningic acid, a GAPDH,
inhibitor, led to autophagy inhibition and increased CASP3
activation and cell death [304]. On the contrary, phagocy-
tosis of 4-HNE- and MDA-modified photoreceptor outer
segments (POS) induced a marked reduction of autophagic
activity by 40% in retinal pigment epithelium (RPE) cells,
which may contribute to RPE cell dysfunction and degener-
ation. In contrast, unmodified POS had no significant effect
on autophagy [305].
2.5.3. Effect of 4-HNE on Senescence. Cellular senescence,
defined as arrest during the cell cycle (G0), is involved
in the complex process of the biological aging of tissues,
organs, and organisms. Senescence is driven by many factors
including oxidative stress, the DNA damage/repair response,
inflammation, mitogenic signals, and telomere shortening.
Telomeres are considered a “biological clock” of the cell
and are shortened by each cell division until a critical
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length is reached and dysfunction ensues. Rapid telomere
shortening may indicate a very high cellular activity. DNA-
repair pathways are then recruited and cells enter senescence,
losing their capacity to proliferate. In addition to cell division,
factors causing telomere shortening include DNA damage,
inflammation, and oxidative stress [306]. Activation of a
DNA damage response including formation of DNA damage
foci containing activated H2A.X (𝛾-histone 2A.X) at either
uncapped telomeres or persistent DNA strand breaks is the
major trigger of cell senescence. 𝛾H2AX is a sensitive marker
of DNA damage, particularly induction of DNA double-
strand breaks [307]. The length of telomeres depends on the
telomerase activity and the catalytic subunit of telomerase
(hTERT) which is strongly upregulated in most human can-
cers [308], and the major consequence of the reactivation of
telomerase activity is that tumor cells escape from senescence.
The expression of c-myc (an activator), mad-1 (a repressor)
and sp-1 (an activator/repressor), which have been shown
to activate hTERT transcription. The formation of 4-HNE-
proteins adducts in general increased as a function of age
[309]. Quantitative evaluation showed that the majority of
senescent hepatocytes (as measured by 𝛾-H2A.X) were also
positive for 4-HNE [310, 311]. 4-HNE can induce premature
senescence by a direct suppression of telomerase activity
affecting the expression of hTERT. In endothelial cells (EC)
isolated and cultured from arterial segments of patients with
severe coronary artery disease, chronic treatment with an
antioxidant (that significantly decreased the levels of lipid
peroxidation, that is, 4-HNE expression) N-acetyl-cystein,
NAC, significantly delayed cellular senescence via decrease of
DNA damage marker (𝛾H2AX), decrease of nuclear p53, and
increase in hTERT activity [312]. In three human leukemic
cell lines (HL-60, U937, and ML-1) [313] and in colon
cancer cells (Caco-2 and HT-29) [314], telomerase activity
and hTERT expression were downregulated by 4-HNE, as a
consequence of downregulation of c-myc mRNA expression
and c-Myc DNA binding activity as well as upregulation of
mad-1 mRNA expression and Mad-1 DNA binding activity.
On the other hand, 4-HNE may induce cellular senescence
through activation of critical cell cycle sentinels that mediate
this process, such as the tumor suppressor proteins p53
(see below), which is well known to play a central role in
senescence [315–320]. p53 protects cells of oxidative stress
and promotes DNA repair. However, when in the cells the
extent of damage overwhelms repair capacities, p53 induces
cell death [315–319]. All these data thus confirmed a cell-
specific association between senescence and 4-HNE.
2.5.4. Effect of 4-HNE on Cell Cycle and Proliferation. In cell
cycle the transition of different phases is driven by several
phase-specific cyclin-CDK (cyclin-dependent kinase) com-
plexes which previously have been activated. In response to
mitogens, cyclin D is activated and phosphorylate retinoblas-
toma protein (RB) which leads to activation of E2F proteins
and the expression of E2F-responsive genes inducing cells to
reenter the cell cycle fromquiescence calledG0, toG1.Activa-
tion of E2F leads to the transcription of cyclin E for transition
from G1 to S phase. Subsequent expression of cyclin A leads
to transition of S to G2 and cyclin B leads G2 to M phases
[321, 322]. The promitotic factor Cdc25 stimulates cell cycle
progression through the activation of cyclin A-Cdk1, cyclin
B-Cdk1, and cyclin E-Cdk2 for entry intoM phase by remov-
ing the inhibitory phosphorylation on Cdk1 and Cdk2. On
the contrary, the anti-mitotic factor (p21, p27, p57) inhibit cell
cycle progression through inhibition of cyclin A–Cdk1, cyclin
B–Cdk1, cyclin E–Cdk2 and cyclin D–Cdk4/6 [321–323]. In
response to 4-HNE, the expression of key components of cell
cycle can be modulated and cells are arrested at G1 or G2.
Several studies showed that in general 4-HNE may induce
cell cycle arrest in malignant cell and inhibition or decrease
of cell proliferation. For example, treatment of HL-60 cells
with 4-HNE (1𝜇M) causes a p53-independent increase of
p21 expression, RB dephosphorylation, progressive reduction
in the amount of free E2F bound to DNA, and a relative
increase in E2F complexes at higher molecular weights with
repressive activity decrease of E2F complexes [324], and
decrease of cyclinD1, cyclinD2, and cyclin A [325]. In human
erythroleukemia cells (K562), 4-HNE treatment increased
p53 and p21 expression and decreased expression of cyclin
D2. The additional decrease of A- and B-cyclin suggests that
the S- and G2-phase were also retarded contributing to the
overall slowdown of the cycle [326]. In human breast cancer
cells (MCF7) the increase in endogenous levels of 4-HNE
caused by treatment with conjugated linoleic acid (CLA)
resulted in the inhibition of cell proliferation through a p53-
dependent mechanism [327]. In human osteosarcoma cells
(HOS), 4-HNE treatment declined gradually the proportion
of cells in mitosis, inhibited proliferation and differentiation,
and increased apoptosis [328]. In malignant cells like hep-
atome cells, with a below-normal content of PUFAs and very
high expression of aldehyde dehydrogenase-3 (ADH3) which
metabolize 4-HNE to DNH, the inhibitory effects of 4-HNE
on cell proliferation are lower, but the inhibition of ADH3
resulted in an increase in the quantity of aldehyde in the cells
and inhibit cell proliferation through the MAPK pathway by
reduction of pRaf-1 and pERK1,2 [329, 330]. Moreover, 4-
HNE has also antiproliferative/differentiative effect mainly in
malignant cell, by affecting the expression of key genes, such
as oncogenes (e.g., c-myc and c-myb) and cyclins. In three
human leukemic cell lines (HL-60, U937, andML-1) [313] and
in colon cancer cells [265, 314], cell proliferationwas inhibited
by 4-HNE, as a consequence of downregulation of c-myc
mRNA. 4-HNE mediated inhibition of cell proliferation in
the HL-60 cell line by downregulation of Notch1, which is
involved in expression of cyclin D1 and c-Myc [331]. In SK-
N-BE human neuroblastoma cells, 4-HNE upregulated p53
family gene expression and p53 gene targets p21 and bax, and
the consequent reduction in S-phase cells and the increased
apoptotic cell proportion; 4-HNE also reduced cyclin D2
expression [332]. In HepG2 cells, 4-HNE decreased both cell
survival and proliferation as evidenced by MTT assays and
EdU incorporation as well as decreased expression of cyclin
D1 and 𝛽-catenin [287]. In K562 cells [333], HL-60 human
leukemic cell line [334], and murine erythroleukemia (MEL)
cells [335], 4-HNE inhibited c-myc expression; a oncogene
is involved in the regulation of cellular multiplication and
transformation (see review of Barrera and co-workers [336]).
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All these effects increased the proportion of G0/G1 cells,
indicating cell cycle arrest at G1 [324, 325, 336, 337]. 4-
HNE-induced G2/M cell cycle arrest was via p21 through a
mechanism (s) that is independent of p53.The cell cycle arrest
leads to apoptotic cell death [338]. Enterococcus faecalis—
infected macrophages produce 4-HNE. This electrophile,
when purified, mediated bystander effects in colonic epithe-
lial cells by generating 𝛾H2AX foci and inducing G2/M cell
cycle arrest. 4-HNE was also associated with mitotic spindle
damage, activation of stathmin, cytokinesis failure, and the
development of tetraploid [339]. In PC3 prostate cancer cell,
4-HNE induced G2/M cell cycle arrest by decreasing p-Cdc2
(entry into M phase is determined by activation of the Cdc2
protein kinase, which requires Cdc2 dephosphorylation);
increased amount of p-H2A.X indicated that 4-HNE induced
apoptotic cell death after a G2/M accumulation [340].
In an opposite way, different studies indicated that 4-
HNE can promote cell proliferation in normal cells, mainly
by upregulation of cyclin or E2F. In cultured primary cortical
neurons, 4-HNE increased the protein levels of phospho-
p53 and cell cycle-related proteins (cyclin D3, cyclin D1,
and CDC25A), caspase-3 activation, PARP cleavage, calpain
activation, serine/threonine kinase 3 (Stk3), and sphingosine
phosphate lyase 1 (Sgpl1) upregulation. NAC decreased cell
death [341]. In smooth muscle cells (SMCs), treatment with
4-HNE enhanced cyclin D1 expression and activation of the
ERK signaling pathway, which were stronger in young SMCs
compared with aged SMCs [342]. 4-HNE induced vascular
smooth muscle cell proliferation [142, 343]. Aldose reductase
(AR) efficiently reduces 4-HNE and GS-HNE. Inhibition
of AR can arrest cell cycle at S phase. In VSMC cells, the
inhibition of AR prevents high glucose (HG-) and/or TNF-
alpha-induced VSMC proliferation by accumulating cells at
the G1 phase of the cell cycle. Treatment of VSMC with 4-
HNEor its glutathione conjugate (glutathionyl (GS-)HNE) or
AR-catalyzed product of GS-HNE, GS-1,4-dihydroxynonane
resulted in increased E2F-1 expression. Inhibition of AR
prevented 4-HNE- orGS-HNE-induced upregulation of E2F-
1. Collectively, these results show that AR could regulate
HG- and TNF-alpha-inducedVSMCproliferation by altering
the activation of G1/S-phase proteins such as E2F-1, cdks,
and cyclins [344]. In airway smooth muscle cells, 4-HNE
is mitogenic by increasing cyclin D1 activity through ERK
signaling pathway [345].
The differential effect of 4-HNE on cell proliferation in
both malignant and nonmalignant cells may be the conse-
quence of lower aldehyde-metabolizing enzymes, deregula-
tion of antioxidant defenses, and mitochondrial metabolism
alteration [132, 346], so that malignant cells are more vulner-
able to further oxidative stress induced by exogenous ROS-
generating agents or inhibitors of the antioxidant systems
[347–349].
2.5.5. 4-HNE-Induced Apoptosis and Necrosis. Apoptosis is
essential programmed cell death process for cells, and its
dysregulation results in too little cell death which may
contribute to carcinogenesis, or too much cell death which
may be a component in the pathogenesis of several diseases.
The alternative to apoptosis or programmed cell death is
necrosis or nonprogrammed cell death, which is considered
to be a toxic process where the cell is a passive victim and
follows an energy-independent mode of death. Depending
on the cell type, DNA damage/repair capacity or cellular
metabolic circumstances 4-HNE can activate proliferative
signaling for cell division and promote cell survival or “stop”
cell division, and after prolonged arrest, cells die fromapopto-
sis. 4-HNEmay induce these processes bymodulating several
transcription factors sensible to stress such as Nrf2, AP-1, NF-
𝜅B, and PPAR or by modulating several signaling pathways,
including MAPK (p38, Erk, and JNK), protein kinase B,
protein kinase C isoforms, cell-cycle regulators, receptor
tyrosine kinases, and caspases. Depending on 4-HNE con-
centrations the cells “end” their lives by apoptosis or necrosis.
For example, the cytotoxicity of 4-HNE to HepG2 cells was
evaluated byMTTassay. 4-HNEconcentrations ranging from
10 to 100 𝜇M gradually decreased cell viability corresponding
to an IC
50
value of 53 ± 2.39 𝜇M. 4-HNE concentrations
of 5–40𝜇M caused apoptotic cell death (measured by flow
cytometry, caspase-3 activation, and PARP cleavage). Finally,
a significant increase in necrotic cell population, that is, 31.8%
and 55.4%, was observed in cells treated with 80 and 100 𝜇M
of 4-HNE, respectively [350]. These results show that 4-HNE
induces apoptosis at low concentration and necrosis at high
concentration.
The two main pathways of apoptosis are extrinsic and
intrinsic pathways. The extrinsic signaling pathways that
initiate apoptosis involve transmembrane receptor-mediated
interactions.This pathway is triggered by the binding of death
ligands of the tumor necrosis factor (TNF) family to their
appropriate death receptors (DRs) on the cell surface; best-
characterized ligands and corresponding death receptors
include FasL/FasR and TNF-𝛼/TNFR1 [351, 352]. The intrin-
sic signaling pathways that initiate apoptosis involve a diverse
array of non-receptor-mediated stimuli. The proapoptotic
member of the Bcl-2 family of proteins, such as Bax, per-
meabilizes the outer mitochondrial membrane. This allows
redistribution of cytochrome c from the mitochondrial inter-
membrane space into the cytoplasm, where it causes activa-
tion of caspase proteases and, subsequently, cell death [352,
353]. Each apoptosis pathway requires specific triggering
signals to begin an energy-dependent cascade of molecular
events. Each pathway activates its own initiator caspase (8,
9) which in turn will activate the executioner caspase-3
[352]. The execution pathway results in characteristic cyto-
morphological features including cell shrinkage, chromatin
condensation, formation of cytoplasmic blebs and apoptotic
bodies, and finally phagocytosis of the apoptotic bodies by
adjacent parenchymal cells, neoplastic cells or macrophages
[352, 353]. A multitude of mechanisms are employed by
p53 to ensure efficient induction of apoptosis in a stage-,
tissue-, and stress-signal-specific manner [354]. 4-HNE-
mediated activation of p53 may be one of the mechanisms
responsible for 4-HNE-induced apoptosis reported in many
cell types. For example, in SH-SY5Y cells 4-HNE-induced
oxidative stress was associated with increased transcriptional
and translational expressions of Bax and p53; these events
trigger other processes, ending in cell death [355]. In RPE
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cells, 4-HNE causes induction, phosphorylation, and nuclear
accumulation of p53 which is accompanied with downregu-
lation of MDM2, a negative regulator of the p53 by blocking
p53 transcriptional activity directly and mediating in the
p53-degradation. Associated proapoptotic genes Bax, p21,
and JNK, which are all signaling components p53-mediated
pathway of apoptosis, are activated in response to exposure to
4-HNE. The induction of p53 by 4-HNE can be inhibited by
the overexpression of either hGSTA4 (in RPE cells) ormGsta4
(in mice) which accelerates disposition of 4-HNE [356].
In CRL25714 cell, 4-HNE induced dose-dependent increase
in the expression of p53 in the cytoplasmic and nuclear
compartments and increase in the expression of Bax [357].
In human osteoarthritic chondrocytes, 4-HNE treatment led
to p53 upregulation, caspase-8, -9, and -3 activation, Bcl-
2 downregulation, Bax upregulation, cytochrome c-induced
release from mitochondria, poly (ADP-ribose) polymerase
cleavage, DNA fragmentation, Fas/CD95 upregulation, Akt
inhibition, and energy depletion. All these effects were
inhibited by an antioxidant, N-acetyl-cysteine [358].
4-HNE can induce apoptosis through the death receptor
Fas (CD95-)mediated extrinsic pathway as well as through
the p53-dependent intrinsic pathway. For detailed infor-
mation of the molecular mechanisms involved in 4-HNE-
induced programmed cell death see review [359]. However,
these mechanisms can be summarized in the following: (i) 4-
HNE is diffusible and can interact with Fas (CD95/Apo1) on
plasma membrane and upregulate and activate its expression
to mediate the apoptotic signaling through activation of
downstream kinases (apoptosis signal-regulating kinase 1 or
ASK1 and JNK), which leads to activation of executioner
caspase-3 and ending in apoptosis; (ii) 4-HNE interacts with
cytoplasmic p53 which causes its induction, phosphoryla-
tion, and nuclear translocation. In the nucleus p53 inhibits
transcription of antiapoptotic genes (Bcl2) and promotes
transcription of proapoptotic genes (Bax) or cell cycle genes
(p21) leading to activation of executioner caspase-3 and
ending in apoptosis or cell cycle arrest, respectively; (iii) 4-
HNE also activates a negative feedback on Fas activation,
by a mechanism involving transcription repressor death
domain-associated protein (Daxx), a nuclear protein which is
associated with DNA-binding transcription factors involved
in stress response. 4-HNE interacts with the Daxx, bound to
heat shock factor-1 (HSF1), translocates Daxx from nucleus
to cytoplasm where it binds to Fas, and inhibits activation of
ASK1 to limit apoptosis.
2.5.6. 4-HNE-Biomolecules Adducts. The preference for
amino acid modification by 4-HNE is Cys ≫ His > Lys
resulting in covalent adducts with the protein nucleophilic
side chain [104, 131, 360, 361]. The reaction between
primary amines and 4-HNE carbonyl carbon groups yields
a reversible Schiff base and the addition of thiol or amino
compounds on 4-HNE 𝛽-carbon atom’ (C of double bond)
produces the corresponding Michael adduct [49]. 4-HNE-
protein adducts can contribute to protein crosslinking and
induce a carbonyl stress. Recently it has been shown that a
membrane associated protein called regulator of G-protein
signaling 4 (RGS4) can be modified by 4-HNE. RGS4, like
other RGS proteins, is responsible for temporally regulating
G-protein coupled receptor signaling by increasing the
intrinsic GTPase activity of G𝛼 subunit of the heterotrimeric
signaling complex. 4-HNE modification of RGS4 at cysteine
residues during oxidative stress can disrupt RGS4 activity
and alter signaling from stressed cells. Possibly 4-HNE acts
as an internal control for aberrant signaling due to excess
RGS4 activity in a variety of pathologies where oxidative
stress is a strong component [362]. Our lab has reported that
4-HNE can affect protein synthesis rates by forming adduct
with eEF2 (see below—cumene hydroperoxide-induced lipid
peroxidation). Large lists of peptides and proteins known to
be modified by 4-HNE are given in the reviews [76, 104, 363]
and including glutathione, carnosine, enzymatic proteins,
carriers proteins, membrane transport proteins, receptor
proteins, cytoskeletal proteins, chaperones, mitochondrial
upcoupling proteins, transcription and protein synthesis
factors, and antioxidant proteins.
It has been reported that 4-HNE also could react
with deoxyguanosine to form two pairs of diastereomeres
adducts (4-HNE-dG 1,2 and 3,4) that further induced
DNA crosslink or DNA-protein conjugates. The mecha-
nism involves a nucleophilic Michael addition of the NH
2
-
group of deoxyguanosine to the CC double bond of 4-
HNE, which yields 6-(1-hydroxyhexanyl)-8-hydroxy-1,N(2)-
propano-2󸀠-deoxyguanosine (HNE-dG), an exocyclic adduct
[49, 133, 134]. HNE-dG adducts have been detected in human
and animal tissues. They are potentially mutagenic and
carcinogenic and can be repaired by the nucleotide excision
repair (NER) pathway [364, 365]. In the presence of peroxides
a different reaction takes place, and the stable end-product
found in the reaction of 4-HNE with DNA bases is etheno-
DNA adducts because 4-HNE is converted by the peroxide
to the corresponding epoxynonanal, which then reacts to
the NH2-group of guanosine followed by cyclization reaction
to form 1, N6-etheno-2󸀠-eoxyadenosine (𝜀dA), and 3, N4-
etheno-2󸀠-deoxycytidine (𝜀dC). These 𝜀-adducts are elimi-
nated by the base excision repair (BER) pathway [49, 366].
Etheno-DNA adduct levels were found to be significantly
elevated in the affected organs of subjects with chronic
pancreatitis, ulcerative colitis, and Crohn’s disease, which
provide promising molecular signatures for risk prediction
and potential targets and biomarkers for preventive measures
[367, 368]. The 4-HNE-DNA adducts in tissue could serve
as marker for the genetic damage produced by endogenous
oxidation of omega-6-PUFAs.
3. The Use of Mammalian Model in Lipid
Peroxidation Research: Compounds
Induced Lipid Peroxidation
The use of mammalian model in lipid peroxidation research
is ideal for studying the consequences of lipid peroxidation
in the context of whole organism and also to analyze their
influence on biomarkers to gain more insight into what
controls the lipid peroxidation and how lipid peroxidation-
related diseases occur. Animal models used to investigate the
16 Oxidative Medicine and Cellular Longevity
+
LH
LH
Cumoxyl
Cumoperoxyl
Cumene
hydroperoxide LP initiation/propagation 
3
1
5
4
2
1
3
H3C C
OH
CH3H3C C CH3H3C C
OOH
CH3
H3C C
OH
CH3 H3C C CH3 H3C C
OOH
CH3
OO∙
O∙
𝛼-Cumyl alcohol
𝛼-Cumyl alcohol
Cumene hydroperoxide
L∙
L∙
O2
M(n+1)Mn
−OH
Figure 7:Mechanisms showing how cumene hydroperoxide produces lipophilic cumoxyl and cumoperoxyl radicals. Cumene hydroperoxide
in presence of transition metal ions produces cumoxyl radical (step 1), which abstracts a hydrogen (H) from a lipid (PUFA) molecule (LH)
generating cumyl alcohol and lipid radical (L∙) that reacts readily with oxygen promoting the initiation or propagation of lipid peroxidation.
(Step 2). Cumoxyl radical can also react with other cumene hydroperoxide molecules to yield cumyl alcohol and cumoperoxyl radical (step
3). Finally, cumoperoxil radical may abstract hydrogen (H) from the closest available lipid to produce a new cumene hydroperoxide and
lipid radical (L∙) which then again affects lipid peroxidation cycling (step 4). Cumoperoxyl radical may also react with oxygen to yield a new
cumoxyl radical thus initiating a chain reaction (step 5).
genetic, physiological, or pathological consequences of lipid
peroxidation should try to control the intrinsic and extrin-
sic influences. Genetic background, diet, environment, and
health status can be strictly controlled in many model organ-
isms. Compared with other model organisms, such as worms
(Caenorhabditis elegans) and flies (Drosophila melanogaster),
the mammalian model is highly comparable to the human
in respect to organ systems, tissues, physiologic systems, and
even behavioral traits. Finally, mammalian model in LP can
be used as a first step toward possible development of drugs
or interventions to control lipid peroxidation process and
prevent disease progression in humans. Various mammalian
models have been developed to study the lipid peroxidation
process.
3.1. Cumene Hydroperoxide-Induced Lipid Peroxidation.
Cumene hydroperoxide (CH) a catalyst used in chemical
and pharmaceutical industry [369] is a stable organic
oxidizing agent with the peroxy function group, –O–O–,
which induces lipid peroxidation. On the existence of
transition-metal, CH can be reduced to form an alkoxyl
radical, which can attack adjacent fatty acid side-chains
to produce lipid radical and cumyl alcohol. The resulting
lipid radical reacts with oxygen to form a lipid peroxyl
radical. And a lipid peroxyl radical reacts with other fatty
acid side-chains to produce a new lipid radical and lipid
hydroperoxide and this chain reaction continues. These lipid
hydroperoxides may undergo transition-metal mediated
one-electron reduction and oxygenation to give lipid peroxyl
radicals, which trigger exacerbating rounds of free radical-
mediated lipid peroxidation (Figure 7). In our lab we have
made extensive use of membrane-soluble CH as a model
compound for lipid hydroperoxides (LOOH), which are
formed in the process of lipid peroxidation during oxidative
stress. CH-induced lipid peroxidation in animals has been
important to study the effect of lipid peroxidation on protein
synthesis through mechanisms that involve regulation of
eElongation Factor 2 (eEF2). It is known that eEF2 plays a
key role as a cytoplasmic component of the protein synthesis
machinery, where it is a fundamental regulatory protein of
the translational elongation step that catalyzes the movement
of the ribosome along the mRNA. One particularity of eEF2
is that it is quite sensitive to oxidative stress and is specifically
affected by compounds that increase lipid peroxidation,
such as cumene hydroperoxide (CH) [370–373]. We have
previously reported that cytotoxic end-products of lipid
peroxidation 4-HNE and MDA are able to form adducts
with eEF2 in vitro [374] and in vivo [309], demonstrating, for
the first time, that this alteration of eEF2 could contribute
to decline of protein synthesis, secondary to LP increase.
The formation of these peroxide-eEF2-adducts is a possible
mechanism responsible of suboptimal hormone production
from hypothalamic-hypophysis system (HHS) during
oxidative stress and aging [375]. The protection of eEF2
alterations by end-products of lipid peroxidation must be
specifically carried out by compounds with lipoperoxyl
radical-scavenging features such as melatonin. We have
reported the ability of melatonin to protect against the
changes that occur in the eEF2 under conditions of lipid
peroxidation induced by CH, as well as decline of protein
synthesis rate caused by lipid peroxidation, demonstrating
that melatonin can prevent the decrease of several hormones
after exposure to LP [376]. In vitro studies carried out in
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our lab also indicated that the antioxidants have different
capacities to prevent eEF2 loss caused by CH [377, 378]. In rat
hippocampal neurons and in response to lipid peroxidation
induced by exposure to CH, eEF2 subcellular localization,
abundance, and interaction with p53 were modified [379].
Finally, using CH-induced lipid peroxidation, we found
that a unique eEF2 posttranslational modified derivative of
histidine (H715) known as diphthamide plays a role in the
protection of cells against the degradation of eEF2, and it
is important to control the translation of IRES-dependent
proteins XIAP and FGF2, two proteins that promote cell
survival under conditions of oxidative stress [380]. Other
labs have used cumene hydroperoxide as a model compound
for lipid hydroperoxides in vivo [381–385].
3.2. Tert Butyl Hydroperoxide. It is an organic oxidizing
agent containing a tertiary butyl group, commonly used in
industry as prooxidizing, a bleaching agent, and an initiator
of polymerization. Tert butyl hydroperoxide is a strong
free radical source and has been utilized to induce lipid
peroxidation in vivomammalian model [386–392].
3.3. Carbon Tetrachloride (CCl
4
). It is a toxic, carcinogenic
organic compound which is used as a general solvent in
industrial degreasing operations. It is also used as pesticides
and a chemical intermediate in the production of refrigerants.
Carbon tetrachloride has been utilized to induce lipid perox-
idation in vivomammalian model [90, 393–398].
3.4. Quinolinic Acid (QA). It is a neuroactive metabolite
of the kynurenine pathway. It is normally presented in
nanomolar concentrations in human brain and cerebrospinal
fluid (CSF) and is often implicated in the pathogenesis of
a variety of human neurological diseases [399]. QA has
been used to induce lipid peroxidation mediated by hydroxyl
radicals in vivomammalian models [400–405].
3.5. Transition Metals Ions. They are essential elements
which, under certain conditions, can have prooxidant effect.
Redox active transition metals have ability to induce and
initiate lipid peroxidation through the production of oxygen
radicals, mainly hydroxyl radical, via Fenton’s/Haber-Weiss
reactions [63, 406]. Transition metal, including copper [407–
410], chromium [411, 412], cadmium [413–416], nickel [417,
418], vanadium [419–421], manganese [59, 422–424], and
iron [59, 407, 425–434] has been utilized to induce lipid
peroxidation in vivomammalian model.
4. Pathological Processes Linked to
MDA and 4-HNE
The accumulation of lipid peroxidation by-product has been
extensively studied and implicated in many toxic tissue
injuries and in pathological processes. An increasing amount
of literature has been published in the field. In particular, the
measurement of freeMDAand/or 4-HNE levels or its derived
protein adducts in biological samples from subjects affected
by several diseases has been widely utilized, indirectly impli-
catingMDAand 4-HNE in the pathogenesis of these diseases.
Table 1 shows a brief extract of studies presented in the
literature in which MDA and 4-HNE have been found to
be significantly modified in pathological contexts. The “big”
challenge in the field of pathological processes is that it is
often difficult to determine whether these lipid peroxidation-
derived aldehydes are actually involved in causing the disease
or are a consequence to it.
5. Conclusions
As conclusion, in this review we summarized the physio-
logical and pathophysiological role of lipid peroxides. When
oxidant compounds target lipids, they can initiate the lipid
peroxidation process, a chain reaction that produces multiple
breakdown molecules, such as MDA and 4-HNE. Among
several substrates, proteins and DNA are particularly suscep-
tible to modification caused by these aldehydes. MDA and 4-
HNE adducts play a critical role inmultiple cellular processes
and can participate in secondary deleterious reactions (e.g.,
crosslinking) by promoting intramolecular or intermolecular
protein/DNA crosslinking that may induce profound alter-
ation in the biochemical properties of biomolecules, which
may facilitate development of various pathological states.
Identification of specific aldehyde-modified molecules has
led to the determination of which selective cellular function
is altered. For instance, results obtained in our lab suggest
that lipid peroxidation affects protein synthesis in all tissues
during aging through a mechanism involving the adduct
formation of MDA and 4-HNE with elongation factor-2.
However, these molecules seem to have a dual behavior,
since cell response can tend to enhance survival or promote
cell death, depending of their cellular level and the pathway
activated by them.
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